© 2021 MJH Life Sciences and AJMC. All rights reserved.
© 2021 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
June 14, 2021
Real-world data confirmed the clinical effectiveness of Celltrion Healthcare’s rituximab biosimilar (Truxima, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL).
June 13, 2021
New studies into chimeric antigen receptor (CAR)–engineered natural killer (NK) cells has shown promising results, explained Ulrike Köhl, PhD, MD, professor of immune oncology and director of the Institute for Clinical Immunology at the University of Leipzig in Germany.
Ibrutinib is currently a standard of care in relapsed/refractory chronic lymphocytic leukemia, but zanubrutinib is an effective second-line and second-generation option, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.
Bispecific T-cell engagers and chimeric antigen receptor T-cell therapies seem destined to move into earlier lines of therapy for multiple myeloma (MM), speakers at the European Hematology Association 2021 Virtual Congress said.
June 12, 2021
The latest phase 2 MAGNOLIA results continue to show strong efficacy and tolerability for the Bruton tyrosine kinase inhibitor in marginal zone lymphoma.
In the frontline setting, daratumumab added to backbone combination therapies has resulted in high rates of minimal residual disease (MRD) negativity, said Ola Landgren, MD, PhD, of the University of Miami and Sylvester Comprehensive Cancer Center.
Using limited data from the ASPEN trial, investigators estimated survival probability and cost-effectiveness for zanubrutinib vs other agents in Waldenström macroglobulinemia.
June 11, 2021
An interim analysis of the phase 3 ALPINE study demonstrated that zanubrutinib has a superior response rate, improved progressive-free survival, and lower rate of atrial fibrillation/flutter compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/ small lymphocytic leukemia (CLL/SLL).
Results from 2 studies presented at this year’s European Hematology Association meeting demonstrate the long-term tolerability and efficacy of the Bruton tyrosine kinase inhibitor.
The populations represented in randomized controlled trials often do not match the populations being treated in the real world due to eligibility criteria, which can be challenging when translating those results to real-world decisions, explained speakers during a session at the European Hematology Association 2021 Virtual Congress.